Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma. Baas P. J Thorac Oncol 2022;17:30-33.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Baas P. Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma. J Thorac Oncol 2022;17:30-33.
PMID: 34930609